SLV-306. Solvay.

Article Details


Tabrizchi R

SLV-306. Solvay.

Curr Opin Investig Drugs. 2003 Mar;4(3):329-32.

PubMed ID
12735234 [ View in PubMed

SLV-306 is an orally active mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development by Solvay SA for the potential treatment of essential hypertension and congestive heart failure. The compound is currently undergoing phase II clinical trials in Belgium.

DrugBank Data that Cites this Article